Zanolimumab

Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma[1].

Product Specifications

CAS Number

[652153-01-0]

Product Name Alternative

Anti-Human CD4 Recombinant Antibody

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/zanolimumab.html

Purity

99.21

Solubility

10 mM in DMSO

Smiles

[Zanolimumab]

Molecular Weight

(144.08 kDa)

References & Citations

[1]Rider DA, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res. 2007 Oct 15;67 (20) :9945-53.